case_images: PMC10959098_01
case_images: Longitudinal anti-rhGAA antibody titers, AST, ALT, and CK trends in Patient 6. AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; CK, Creatine kinase; ERT, enzyme replacement therapy.
case_images: fimmu-15-1360369-g001.jpg
case_images: PMC10959098_02_fimmu-15-1360369-g001.jpg
case_images: f1
case_images: Due to rising antibody titers, ITI with bortezomib, rituximab, methotrexate, and IVIG was initiated at 13 weeks of ERT as previously published ( Figure 1 ).
case_images: PMC10959098_02
case_images: Longitudinal anti-rhGAA antibody titers, AST, ALT, and CK trends in Patient 6. AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; CK, Creatine kinase; ERT, enzyme replacement therapy.
case_images: fimmu-15-1360369-g001.jpg
case_images: PMC10959098_02_fimmu-15-1360369-g001.jpg
case_images: f1
case_images: Due to rising antibody titers, ITI with bortezomib, rituximab, methotrexate, and IVIG was initiated at 13 weeks of ERT as previously published ( Figure 1 ).
case_images: Longitudinal anti-rhGAA antibody titers, AST, ALT, and CK trends in Patient 8. AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; CK, Creatine kinase; ERT, enzyme replacement therapy.
case_images: fimmu-15-1360369-g002.jpg
case_images: PMC10959098_02_fimmu-15-1360369-g002.jpg
case_images: f2
case_images: Anti-rhGAA antibody titers decreased from a peak titer of 25,600 (week 10) and remained negative from week 57 until the most recent follow-up (134 weeks) ( Figure 2 ).